CDK2-IN-41

• Description :

  CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Field of Research :

  Cancer

• Smiles :

  N#CC1=C2C(CNCC2)=C(C=C1N3CCCCC3)C4=CC=CS4

• Molecular Formula :

  C19H21N3S

• Molecular Weight :

  323.46

• References & Citations :

  [1]Ananta, et al. Design, Synthesis, and Simulation of Functionalized 1, 2, 3, 4‐Tetrahydroisoquinolines to Treat Acute Leukemia Cells[J]. ChemistrySelect, 2025, 10 (7) : e202404024.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK2